Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Department of Translational Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy.
Int J Mol Sci. 2022 Mar 24;23(7):3553. doi: 10.3390/ijms23073553.
Early post-transplant is the critical phase for the success of hematopoietic stem cell transplantation (HSCT). New viral infections and the reactivations associated with complete ablation of the recipient's T-cell immunity and inefficient reconstitution of the donor-derived system represent the main risks of HSCT. To date, the pharmacological treatments for post-HSCT viral infection-related complications have many limitations. Adoptive cell therapy (ACT) represents a new pharmacological strategy, allowing us to reconstitute the immune response to infectious agents in the post-HSC period. To demonstrate the potential advantage of this novel immunotherapy strategy, we report three cases of pediatric patients and the respective central nervous system complications after donor lymphocyte infusion.
移植后早期是造血干细胞移植（HSCT）成功的关键阶段。新的病毒感染和与受体 T 细胞免疫完全消融以及供体衍生系统重建效率低下相关的再激活是 HSCT 的主要风险。迄今为止，针对 HSCT 后与病毒感染相关并发症的药物治疗存在许多局限性。过继细胞治疗（ACT）代表了一种新的药物治疗策略，使我们能够在 HSCT 后重建对感染因子的免疫反应。为了证明这种新型免疫治疗策略的潜在优势，我们报告了三例接受供者淋巴细胞输注后的儿科患者及其各自的中枢神经系统并发症。
